Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1686)

Donna Glover, Joseph Ibrahim, John Kirkwood, John Glick, Daniel Karp, James Stewart, Marian Ewell, Ernest Borden

Research output: Contribution to journalArticle

26 Scopus citations


This study was designed to evaluate the toxicity and efficacy of cisplatin and WR-2721 in contrast to cisplatin alone for the therapy of measurable metastatic melanoma. Ninety-four patients with metastatic melanoma were randomized to receive either cisplatin at a dose of 150 mg/m2 and WR-2721 at a dose of 910 mg/m2, or cisplatin alone at a dose of 120 mg/m2. WR-2721 did not mitigate the toxic effects of cisplatin, and toxicity was increased in the WR-2721 plus cisplatin arm compared with cisplatin alone. For patients receiving cisplatin alone, the response rate was 16.3%; for those receiving cisplatin plus WR-2721, the response rate was 23.3%. The duration of response was 7.3 months. Median survival in the intent-to-treat analysis was 7.58 months. The study was terminated after accrual of 94 patients, with inadequate power to define an effect of WR-2721 on the duration of response and survival. In conclusion, cisplatin with WR-2721 showed an improved response rate over cisplatin alone. The lack of improved duration of response or impact on survival may be the result of the limited improvement of efficacy with the higher dosage of cisplatin in conjunction with WR-2721, or the limited number of patients accrued to this study. These factors, coupled with the failure of the combination to diminish toxicity, dampen enthusiasm for this combination.

Original languageEnglish (US)
Pages (from-to)619-626
Number of pages8
JournalMelanoma research
Issue number6
StatePublished - Dec 1 2003



  • Amifostine
  • Chemotherapy
  • Melanoma
  • WR2721

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this